Anti-EGFR 抗体

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-EGFR antibody (AB131498)

Immunohistochemical analysis of paraffin embedded Human breast carcinoma tissue labelled with ab131498 at 1/50 diluton (left) and ab131498 preincubated with blocking peptide (right).

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-EGFR antibody (AB131498)

Immunifluorescence analysis of methanol fixed MCF cells using ab131498 at 1/100 dilution.

• WB

Unknown

Western blot - Anti-EGFR antibody (AB131498)

All lanes:

Western blot - Anti-EGFR antibody (ab131498) at 1/500 dilution

Lane 1:

HUVEC extract

Lane 2:

MDA cell extract

Predicted band size: 134 kDa

false

• WB

CiteAb

Western blot - Anti-EGFR antibody (AB131498)

Western Blotting using Anti-EGFR antibody, ab131498. Publication image from Ryu, W. J. et al., 2020, Exp Mol Med, 32457491. Legend direct from paper.

Effects of KYA1797K on TNBC PDCs and cell lines.a, b TNBC cells were cultured and treated with 5 or 25 µM KYA1797K for 24 h. Immunoblot analyses of whole-cell lysates (WCLs) with the indicated antibodies. c, d PDCs, human TNBC cell lines, and 4T1 mouse TNBC cells were dose-dependently treated with KYA1797K. Cell proliferation was measured and quantified using MTT assay (n = 3). e, f Colony-formation assay was performed in TNBC cells treated with 5 or 25 µM KYA1797K for 14 days. The colonies in e and f were photographed and quantified from independent experiments (mean ± SEM; n = 3) based on two-sided Student’s t test between control and experimental samples, respectively. *P < 0.05, **P < 0.005., ***P < 0.0005. M = mesenchymal-like, MSL = mesenchymal stem-like, BL = basal-like.

false

• WB

CiteAb

Western blot - Anti-EGFR antibody (AB131498)

Western Blotting using Anti-EGFR antibody, ab131498. Publication image from Ryu, W. J. et al., 2020, Exp Mol Med, 32457491. Legend direct from paper.

Effects of KYA1797K on the growth of tumors derived from a TNBC cell line xenograft and a patient-derived xenograft (PDX).Mice-bearing TNBC tumors established from MDA-MB-468 cells or patients who showed resistance to adjuvant chemotherapy were treated with vehicle or KYA1797K (25 mg/ml) when the tumor burden reached a volume of 150–200 mm3 (MDA-MB-468 : vehicle n = 3, KYA1797K n = 4; PDX-1 : vehicle n = 3, KYA1797K n = 3). KYA1797K was administered as described in “Materials and methods”. Subcutaneous tumor volumes were measured using calipers. a, e Tumor volumes were measured for 35 days (MDA-MB-468) or 42 days (PDX-1). b, f IB analyses with the indicated antibodies using WCLs of MDA-MB-468 cells or PDX-1 tumors. IHC analyses were performed on formalin-fixed 4-µm paraffin sections of tumors-derived MDA-MB-468 cells (c, d) or PDX-1 (g, h) using the indicated antibodies. Mean fluorescence intensity for each marker was quantified by using a ZEN microscope software (Carl Zeiss Microscopy). Data values represent the mean ± SEM. *P < 0.05, **P < 0.005., ***P < 0.0005.

false